Mylan Inc. has now appointed Rakesh Bamzai, as President, India Commercial and Emerging Markets. He will be based at the Mylan office in Bangalore, India.
Bamzai was earlier President-Marketing, Biocon Ltd and resigned to join Mylan Inc on January 2, 2014. He has been associated with the Indian and global biopharmaceutical industry for over 20 years. His business experience spans over 100 countries including US, EU and emerging markets; a diverse product portfolio comprising biologics, small molecules and branded formulations and key therapies like endocrinology, cardiology, oncology, nephrology and auto-immune.
Since 2009, Biocon and Mylan have been co-developing a high value portfolio of biosimilar monoclonal antibodies and complex biologics, comprising trastuzumab, pegfilgrastim, bevacizumab, adalimumab and etanercept.
As President-Marketing, Biocon, Bamzai played a key role in building a global biopharmaceutical business. In the leadership role, he was managing a team of over 2000 people across functional areas and geographies. He also spearheaded many strategic partnerships which enabled Biocon to gain wider global access and greater market penetration for its biopharmaceuticals business.
At Mylan, Bamzai will be responsible for all commercial operations in India and emerging markets. These will include their recently established commercial business in India in which Mylan plans to launch business units in diverse therapy areas.
“Many of us at Mylan have had a firsthand opportunity to work with Rakesh over the course of our strategic partnership with Biocon, and have observed his strong business and marketing acumen, his strategic insight and outstanding leadership skills. In this new role of overseeing all of Mylan’s commercial operations in India and emerging markets, we believe that Rakesh will add significant value to Mylan,” said Rajiv Malik, president, Mylan.
Bamzai said, “Having collaborated with Mylan during my tenure at Biocon, there are significant opportunities seen in my new role in India and other emerging markets. I believe Mylan’s commitment to quality and to setting new standards for innovation, reliability and service for patients and physicians in India will further distinguish the company from its peers. I look forward to supporting Mylan’s continued expansion and differentiation in these exciting growth markets.”
Bamzai has been recipient of multiple awards including the Marketing Professional of the year-2004 by Forbes at the India Brand Summit, Pride of the Industry Award in 2009 and India’s Greatest Brand BuilderAward at the Asia Brand Congress held in Singapore in 2010. More recently, he was one of the recipients of the distinguished The Greatest Corporate Leader of India 2013 awarded by Indiagreatest.com.